FGFR2 and cholangiocarcinoma: According to the latest 2020 National Comprehensive Cancer Network (NCCN) guidelines (United States), if FGFR2 gene fusion or rearrangement is clinically detected in cholangiocarcinoma, the targeted drug pemigatinib can be used for treatment, and there is a favorable response (Abou-Alfa et al., 2020; Romero, 2020).